PlainPharmaWatch

CMS Open Payments · Program Year 2024

Shorla Oncology Inc.

Shorla Oncology Inc. reported $797.92 across General Payments, Research, and Ownership to 31 physicians and teaching hospitals across 31 transactions.

See the rankings → How this is sourced
$797.92
All-tracks total
31
Transactions
31
Recipients
#1856
of 1,925 companies

Shorla Oncology Inc. reported $797.92 across all CMS Open Payments tracks (General + Research + Ownership) to 31 physicians and teaching hospitals in Program Year 2024 - ranking #1856 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $797.92, averaging $25.74 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer shorla-oncology-inc Shorla Oncology Inc.

$797.92 · #1856/1,925 · 0.0% industry · PY2024

  • TOT $797.92
  • RANK #1856
  • SHARE 0.0%
  • TXN 31
  • RCP 31
  • CAT 1
  • GEN $797.92
  • TOP1 8.0%
  • PY 2024

Volume peers

Nearest volume peer: SCA Pharmaceuticals, LLC ($806.08)

McKesson Medical-Surgical Mi…$837.57Nuo Therapeutics$833.09Precision Medical Products I…$832.29SCA Pharmaceuticals, LLC$806.08Shorla Oncology Inc. (this)$797.92
All-tracks payment totals near Shorla Oncology Inc. (CMS Open Payments PY2024)

Shorla Oncology Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Shorla Oncology Inc.

$797.92: that is what Shorla Oncology Inc. reported in payments to 31 physicians and teaching hospitals during Program Year 2024, spread across 31 transactions ($25.74 per transaction, $25.74 per recipient). The company sits at rank #1856 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

Of the 1 general-payment categories charted below, "Food and Beverage" is the largest at $797.92 across 31 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Shorla Oncology Inc. made 1 types of general payments. "Food and Beverage" is the largest category at $797.92, 100.0% of General Payments.

How Shorla Oncology Inc. divides its payments

How the reported total splits across payment categories

1. Food and Beverage$797.92
Payment Type Amount Transactions
Food and Beverage $797.92 31

Recipient Concentration in General Payments

The five largest recipient relationships account for $227.49 (28.5%) of $797.92 in this company's General Payments records across 29 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Shorla Oncology Inc.

The five named recipients with the highest reported General Payments from this company

Neha a Pansuria$64.17Barbara J Phelps$45.43Dedri Markita Ivory$45.43Lisa Kaye Proffitt$38.37Jason Su$34.09
  1. 1

    Neha a Pansuria

    $64.17 across 2 reported transactions

  2. 2

    Barbara J Phelps

    $45.43 across 1 reported transactions

  3. 3

    Dedri Markita Ivory

    $45.43 across 1 reported transactions

  4. 4

    Lisa Kaye Proffitt

    $38.37 across 1 reported transactions

  5. 5

    Jason Su

    $34.09 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Shorla Oncology Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Shorla Oncology Inc..

Providence Medical Technology, Inc.

HHI 404

Cerapedics Inc.

HHI 405

PROCEPT BioRobotics Corporation

HHI 405

icotec Medical Inc.

HHI 403

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Shorla Oncology Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Shorla Oncology Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.